University of Groningen RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer

Erik J. van Helden,Lindsay Angus,C. Willemien Menke-van der Houven van Oordt,A. M. Heideman,Eline Boon,Suzanne C. van Es,Sandra A. Radema,Carla M. L. van Herpen,Derk Jan A. de Groot,Elisabeth G. E. de Vries,Maurice P. H. M. Jansen,Stefan Sleijfer,Henk M. W. Verheul

Molecular Oncology（2019）

引用 23|浏览3

暂无评分

摘要

RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer van Helden, Erik J.; Angus, Lindsay; van Oordt, C. Willemien Menke-van der Houven; Heideman, Danielle A. M.; Boon, Eline; van Es, Suzanne C.; Radema, Sandra A.; van Herpen, Carla M. L.; de Groot, Derk Jan A.; de Vries, Elisabeth G. E. Published in: Molecular oncology

查看译文

关键词

biomarkers,BRAF,cell‐free DNA,cetuximab,colorectal cancer,RAS mutations

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要